Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 7/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.59 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 2/20 | 0.50 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | IL1B | P01584 | 1/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19370772 | 0.90 | CRBN (0.61) | MAP1LC3BCRBNDDB1BRD4IKZF1 | |
| SCHEMBL19370687 | 0.90 | CRBN (0.61) | MAP1LC3BCRBNDDB1BRD4IKZF1 | |
| SCHEMBL31065034 | 0.90 | CRBN (0.56) | MAP1LC3BCRBNDDB1STAT3BRD4 | |
| SCHEMBL13643751 | 0.89 | CRBN (0.59) | MAP1LC3BCRBNDDB1STAT3BRD4 | |
| SCHEMBL23772833 | 0.88 | STAT3 (0.57) | MAP1LC3BCRBNDDB1STAT3BRD4 | |
| SCHEMBL25756441 | 0.88 | STAT3 (0.57) | MAP1LC3BCRBNDDB1STAT3BRD4 | |
| SCHEMBL23772804 | 0.88 | STAT3 (0.57) | MAP1LC3BCRBNDDB1STAT3BRD4 | |
| SCHEMBL23772935 | 0.88 | STAT3 (0.57) | MAP1LC3BCRBNDDB1STAT3BRD4 | |
| SCHEMBL23729386 | 0.88 | CRBN (0.72) | MAP1LC3BCRBNDDB1STAT3BRD4 | |
| SCHEMBL22580836 | 0.88 | CRBN (0.58) | MAP1LC3BCRBNDDB1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210085700-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| EP-3738594-A1 | TARGETED THERAPEUTICS HAVING AN HSP90 LIGAND AS BINDING MOIETY | Madrigal Pharmaceuticals, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10828315-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3035938-B1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS INC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20170056510-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-02 | — | — | US | disclosed |
| WO-2015038649-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085700-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | MAP1LC3B 145/4885CRBN 2162/4885DDB1 157/4885 |
| US-10828315-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | MAP1LC3B 145/4885CRBN 2162/4885DDB1 157/4885 |
| US-20170056510-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | MAP1LC3B 145/4885CRBN 2162/4885DDB1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.